Ninth Circuit Dismisses Class Certification Bid in Cymbalta Suit

The Ninth Circuit Court of Appeals dismissed a bid for class certification in a lawsuit against Eli Lilly last week.

The suit accused the drugmaker of downplaying the withdrawal risks of its antidepressant Cymbalta.

According to the complaint, the labels understate the percentage of users the symptoms effect at only 1 or 2 percent, when in fact it is closer to 50 percent.